Physician profile
Michael E Tedder
NPI 1962463091
$5,281.31
in general payments reported to CMS, 2019-2025
24 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $577 · 2021: $675 · 2022: $1,132 · 2023: $1,053 · 2024: $695 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,073.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,035.38 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $910.96 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $559.09 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $438.11 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $351.53 | 2019-2025 | Ozempic, Wegovy |
| Pfizer INC. | $293.67 | 2019-2023 | |
| Abbott Laboratories | $272.12 | 2022-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.12 | 2019-2023 | Ofev |
| Medtronic, INC. | $162.11 | 2024 | Signia, Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $148.62 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $143.48 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $112.72 | 2019-2022 | |
| Lilly USA, LLC | $104.53 | 2020-2024 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $103.49 | 2019-2024 | Veozah |
| Allergan, INC. | $102.26 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $92.49 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.46 | 2023-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $42.85 | 2022-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $41.83 | 2019-2020 | |
| Genentech USA, INC. | $36.67 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $34.77 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $24.72 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $14.34 | 2022 | |
| Eisai INC. | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tedder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.